Targeted therapy in chronic myeloid leukemia.

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Chronic myeloid leukemia (CML) is driven by the Philadelphia chromosome and Bcr-Abl fusion protein.
• Targeted therapies inhibiting Bcr-Abl tyrosine kinase activity have revolutionized CML management.
• Imatinib is the standard first-line therapy, but resistance, often due to BCR-ABL mutations, can occur.

Purpose of the Study:

• To review the molecular basis of CML and the development of targeted therapies.
• To discuss the efficacy of imatinib and the challenges of imatinib resistance.
• To explore newer tyrosine kinase inhibitors and future treatment strategies for CML.

Main Methods:

• Literature review of studies on CML pathogenesis and targeted therapies.
• Analysis of clinical trial data for imatinib, dasatinib, and nilotinib.
• Discussion of emerging agents and personalized treatment approaches.

Main Results:

• Imatinib induces durable responses but resistance is a significant issue.
• Second-generation tyrosine kinase inhibitors like dasatinib and nilotinib show efficacy in imatinib-resistant CML.
• Ongoing development of agents like bosutinib and INNO-406 offers further therapeutic avenues.

Conclusions:

• Targeted therapies have dramatically improved CML prognosis.
• Personalized treatment strategies, considering factors like BCR-ABL mutations, are becoming feasible.
• Future CML treatment may involve combination therapies to overcome resistance and enhance efficacy.